Trofinetide

Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials

Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials

A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome

Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study

Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome

A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects

A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome

Population pharmacokinetics of NNZ-2566 in healthy subjects

Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome

Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome

Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives

Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation

Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects

Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study

Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials

Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study

Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy

Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome

Trofinetide: First Approval

Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need

Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study

A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)

Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis

Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome

Safety Profiles of Trofinetide in Pediatric Rett Syndrome Population: A Real-World Postmarketing Pharmacovigilance Analysis

Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome

Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome